Top

Published in:

01-05-2006

Is Surgery Beneficial for MEN1 Patients with Small (≤2 cm), Nonfunctioning Pancreaticoduodenal Endocrine Tumor? An Analysis of 65 Patients from the GTE

Authors: Frederic Triponez, MD, Pierre Goudet, MD, David Dosseh, MD, Patrick Cougard, MD, Catherine Bauters, MD, Arnaud Murat, MD, Guillaume Cadiot, MD, Patricia Niccoli-Sire, MD, Alain Calender, MD, Charles A. G. Proye, MD, FRCS (Eng), FRCS Ed (Hon)

Published in: World Journal of Surgery | Issue 5/2006

Abstract

Background

The management of small, nonfunctioning pancreaticoduodenal endocrine tumors (NFPET) in multiple endocrine neoplasia type 1 (MEN1) patients is still controversial. We therefore investigated the effect of surgery on survival and tumor progression in MEN1 patients with NFPET ≤2 cm by analyzing data from the Groupe des Tumeurs Endocrines (GTE) registry.

Materials and Methods

Among 579 MEN1 patients in the registry, 65 had NFPET ≤ 2 cm. Fifteen (23%) underwent pancreatectomy, 9 at least segmental pancreatectomies and 6 biopsies or enucleations (the surgery group), and 50 (77%) were followed conservatively (the no surgery group). Age at MEN1 and NFPET diagnosis was similar in both groups, as was size of the primary tumor. Seven (10.8%) patients had metastases. Five metastases were synchronous, and 2 (one in each group) were metachronous. Tumor size was similar in patients with or without metastasis.

Results

There was no perioperative mortality. The average follow-up time after NFPET diagnosis was 6.7 years in the surgery group and 3.3 years in the no surgery group. Three (4.6%) patients died during follow-up, 2 due to NFPET and 1 due to thymus tumor. The 2 patients who died of NFPET had undergone pancreatic surgery at the time of NFPET diagnosis. The 2 groups did not differ significantly with respect to tumor progression [5/15 (33%) vs 6/38 (16%), P = 0.16]. Overall life expectancy of patients with NFPET ≤2 cm was not different than that of the 229 MEN1 patients in the registry without any pancreaticoduodenal tumor (P = 0.33).

Conclusions

This study suggests that surgery may not be beneficial for MEN1 patients with NFPET ≤2 cm.

Doherty GM, Thompson NW. Multiple endocrine neoplasia type 1: duodenopancreatic tumours. J Intern Med 2003;253(6):590–598CrossRefPubMed

Lairmore TC, Chen VY, DeBenedetti MK, et al. Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2000;231(6):909–918CrossRefPubMed

Akerstrom G, Hessman O, Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg 2002;386(8):558–569CrossRefPubMed

Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN1 patients from the GTE with isolated non functioning tumors of the pancreas. Ann Surg 2006; 243(2):265–272CrossRefPubMed

Thomas-Marques L, Murat A, Delemer B, et al. Prospective endoscopic ultrasonographic evaluation of the frequency of non-functioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006;101(2)266–273

Wilkinson S, Teh BT, Davey KR, et al. Cause of death in multiple endocrine neoplasia type 1. Arch Surg 1993;128(6):683–690PubMed

Doherty GM, Olson JA, Frisella MM, et al. Lethality of multiple endocrine neoplasia type I. World J Surg 1998;22(6):581–586CrossRefPubMed

Dean PG, van Heerden JA, Farley DR, et al. Are patients with multiple endocrine neoplasia type I prone to premature death? World J Surg 2000;24(11):1437–1441CrossRefPubMed

Doherty GM. Multiple endocrine neoplasia type 1: duodenopancreatic tumors. Surg Oncol 2003;12(2):135–143CrossRefPubMed

10.

Mutch MG, Frisella MM, DeBenedetti MK, et al. Pancreatic polypeptide is a useful plasma marker for radiographically evident pancreatic islet cell tumors in patients with multiple endocrine neoplasia type 1. Surgery 1997;122(6):1012–1019CrossRefPubMed

11.

GTE. Recommendation booklet on MEN 1. 2004. Available at: http://www.sf-endocrino.net/sfe/index.php?pageID=50c46b0ac0cee215b20b5627b461b2c3. Accessed July 07, 2005

12.

Hausman MS Jr., et al. The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 2004;136(6):1205–1211CrossRefPubMed

13.

Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346(15):1128–1137CrossRefPubMed

14.

Kendall DM, Sutherland DE, Najarian JS, et al. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N Engl J Med 1990;322(13):898–903PubMedCrossRef

15.

Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol 2004;18(5):947–955CrossRefPubMed

16.

Goudet P, Peschaud F, Mignon M, et al. Gastrinomas in multiple endocrine neoplasia type-1. A 127-case cohort study from the endocrine tumor group (GTE). Ann Chir 2004;129(3):149–155CrossRefPubMed

17.

Wiedenmann B, Jensen RT, Mignon M, et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 1998;22(3):309–318CrossRefPubMed

18.

Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86(12):5658–5671CrossRefPubMed

19.

NCCN. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Neuroendocrine Tumors version 2. 2005; http://www.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf, accessed July 11th, 2005

20.

Gauger PG, Scheiman JM, Wamsteker EJ, et al. Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. Br J Surg 2003;90(6):748–754CrossRefPubMed

21.

Cadiot G, Lebtahi R, Sarda L, et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D’etude Du Syndrome De Zollinger-Ellison. Gastroenterology 1996;111(4):845–854CrossRefPubMed

22.

Langer P, Kann PH, Fendrich V, et al. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg 2004;28(12):1317–1322CrossRefPubMed

23.

Ballard HS, Fame B, Hartsock RJ. Familial multiple endocrine adenoma-peptic ulcer complex. Medicine (Baltimore) 1964;43:481–516

24.

Skogseid B, Oberg K, Akerstrom G, et al. Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization? World J Surg 1998;22(7):673–677CrossRefPubMed

Title: Is Surgery Beneficial for MEN1 Patients with Small (≤2 cm), Nonfunctioning Pancreaticoduodenal Endocrine Tumor? An Analysis of 65 Patients from the GTE
Authors: Frederic Triponez, MD
Pierre Goudet, MD
David Dosseh, MD
Patrick Cougard, MD
Catherine Bauters, MD
Arnaud Murat, MD
Guillaume Cadiot, MD
Patricia Niccoli-Sire, MD
Alain Calender, MD
Charles A. G. Proye, MD, FRCS (Eng), FRCS Ed (Hon)
Publication date: 01-05-2006
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 5/2006
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-005-0354-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Is Surgery Beneficial for MEN1 Patients with Small (≤2 cm), Nonfunctioning Pancreaticoduodenal Endocrine Tumor? An Analysis of 65 Patients from the GTE

Abstract

Background

Materials and Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Materials and Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2006

Endoscopic Lateral Approach Thyroid Lobectomy: Safe Evolution from Endoscopic Parathyroidectomy

Selective Modified Radical Neck Dissection for Papillary Thyroid Cancer—Is Level I, II and V Dissection Always Necessary?

Selective Use of Adrenal Venous Sampling in the Lateralization of Aldosterone-producing Adenomas

Total Parathyroidectomy Without Autotransplantation for Renal Hyperparathyroidism: Experience with a qPTH-controlled Protocol

Hypocalcaemia and Parathyroid Hormone Assay Following Total Thyroidectomy: Predicting the Future

Negative Imaging Studies for Primary Hyperparathyroidism Are Unavoidable: Correlation of Sestamibi and High-Resolution Ultrasound Scanning with Histological Analysis in 150 Patients